Objective: The fragility index (FI), a minimum number of events in 1 arm of a clinical trial required to revert the statistically significant result to nonsignificant, has recently been developed as an easy-to-understand novel metric to evaluate the robustness of randomized controlled trials (RCTs). Here, we evaluated the FI of RCTs in the field of neurology, particularly in studies of ischemic stroke. Methods: Previous literature published between June 1, 2012 and May 31, 2018 were reviewed from the MEDLINE database by the authors.

Read More...

Leave a comment.

Your email address will not be published. Required fields are marked*

Andoird App
Loading...